Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses

Berhoune, Malik; Aboudagga, Haîl; Jacob, Aude; Grandhay, Jean-Pierre; Dayot, Corinne; Prognon, Patrice; Bonan, Brigitte
April 2011
American Journal of Health-System Pharmacy;4/1/2011, Vol. 68 Issue 7, p557
Academic Journal
The article discusses the results of a data analysis at the Georges Pompidou European Hospital in France, which compared the number and cost of ungiven doses in same-day order and advance approval procedures. The analysis revealed a higher percentage of ungiven doses in the oncology unit which used the same-day approval procedure. The article highlights that using an advance approval system could reduce patients' waiting time and allow personnel to efficiently manage their workload.


Related Articles

  • Lean methodology in i.v. medication processes in a children's hospital. L'Hommedieu, Timothy; Kappeler, Karl // American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2115 

    Purpose. The impact of lean methodology in i.v. medication processes in a children's hospital was studied. Methods. Medication orders at a children's hospital were analyzed for 30 days to identify the specific times when most medications were changed or discontinued. Value-stream mapping was...

  • A three-year study of a first-generation chemotherapy-compounding robot. NURGAT, ZUBEIR; FARIS, DIMA; MOMINAH, MAHER; VIBAR, ARRIS; AL-JAZAIRI, ABDULRAZAQ; EWING, SHEENA; ASHOUR, MOHAMMED; QAISI, SHROUQ KAMEL; BALHARETH, SAKRA; AL-JEDAI, AHMED // American Journal of Health-System Pharmacy;6/15/2015, Vol. 72 Issue 12, p1036 

    Purpose. Results of a performance evaluation of an automated system for compounding antineoplastic preparations are reported. Methods. Three years after the pharmacy department of a hospital in Saudi Arabia installed an i.v.-compounding robot (CytoCare, Health Robotics), data captured by the...

  • Inhouse authorization center to improve reimbursement for outpatient chemotherapy infusions. Desai, Shetal S. // American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p828 

    Purpose. The use of an inhouse authorization center to improve reimbursement for outpatient chemotherapy infusions is described. Summary. Investigation of current processes revealed deficiencies in the coordination of an insurance authorization process at Norris Cancer Hospital, as chemotherapy...

  • Intravenous chemotherapy preparation errors: Patient safety risks identified in a pan-Canadian exploratory study. White, Rachel; Cassano-Piché, Andrea; Fields, Anthony; Cheng, Roger; Easty, Anthony // Journal of Oncology Pharmacy Practice;Feb2014, Vol. 20 Issue 1, p40 

    Background: This exploratory study was launched following a critical chemotherapy medication incident to thoroughly and proactively examine the current processes for ordering, preparing, labeling, verifying, administering, and documenting ambulatory intravenous chemotherapy in Canada, and to...

  • gemcitabine.  // Royal Society of Medicine: Medicines;2002, p265 

    This article provides information on gemcitabine, a cytotoxic/anticancer drug which is used in the clinical management of locally advanced or metastatic non-small cell lung cancer. It is also used for advanced metastatic adenocarcinoma of the pancreas. The drug is administered through injection.

  • Zavedos.  // Royal Society of Medicine: Medicines;2002, p575 

    This article presents information on the drug Zavedos. This drug is proprietary, prescription-only preparation of the anticancer drug idarubicin hydrochloride. It can be used to treat various cancers, and is available as capsules and in a form for injection.

  • CMS relaxes short-cycle dispensing plan, delays deadline. Traynor, Kate // American Journal of Health-System Pharmacy;5/15/2011, Vol. 68 Issue 10, p867 

    No abstract available.

  • ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Chicaíza-Becerra, Liliana; García-Molina, Mario; Gamboa, Oscar; Castañeda-Orjuela, Carlos // Revista de Salud Pública;apr2014, Vol. 16 Issue 2, p270 

    Objective Breast cancer (BC) and metastatic breast cancer (MBC) are significant causes of deaths amongst women worldwide, including developing countries. The cost of treatment in the latter is even more of an issue than in higher income countries. ErbB2 overexpression is a marker of poor...

  • Minimizing waste during preparation of blinatumomab infusions. Marini, Bernard L.; Wechter, Andrew R.; Burke, Patrick W.; Bixby, Dale; Perissinotti, Anthony J. // American Journal of Health-System Pharmacy;1/15/2016, Vol. 73 Issue 2, p19 

    The article discusses the approval of blinatumomab, the most expensive oncology drugs and a first-in-class, novel CD19-directed bispecific T-cell engager approved for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics